All In Biotech

Drug Trial Radar · NCT07246525

Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission

Cluster Randomized Trial of Intermittent Preventive Treatment of Malaria in School-age Children to Improve the Health of Students and Decrease Community Transmission

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 4,800 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

4,800

Planned (sponsor's estimate)

Start

Sep 22, 2026

Primary completion

Nov 15, 2029

Study completion Nov 15, 2029

Sponsor

Lead sponsor
University of California, San FranciscoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Allergy and Infectious Diseases (NIAID); Infectious Diseases Research Collaboration, Uganda; Ministry of Health, Uganda
First posted
Nov 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, up to 17 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The CRITICal study aims to estimate the effectiveness of intermittent preventive treatment in school children (IPTsc) with dihydroartemisinin-piperaquine (DP) for reducing community level malaria burden. Given that school-aged children are the primary drivers of transmission, the study hypothesis is that IPTsc will reduce this infectious reservoir and thus the burden of malaria in persons of all ages in surrounding communities.

Conditions

  • Malaria

Interventions

  • dihydroartemisinin-piperaquineDrug

    D-Artepp, is manufactured by Guilin Pharmaceutical Co Ltd, and is prequalified by the WHO and approved for use in Uganda by the National Drug Authority. Standard treatment doses of DP (once a day x 3 days) will be administered using weight-based guidelines targeting a total dose of 6.4 mg/kg dihydroartemisinin and 51.2 mg/kg of piperaquine as per manufacturer's instructions.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of cases of laboratory-confirmed malaria diagnosed among patients residing in the target area during the period the intervention is implementedTime frame: 24 months after intervention implemented

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Infectious Diseases Research Collaboration

    Kampala, Uganda · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.